Progesterone to prevent miscarriage in women with early pregnancy bleeding: the PRISM RCT

Arri Coomarasamy,1* Hoda M Harb,1 Adam J Devall,1 Versha Cheed,2 Tracy E Roberts,2 Ilias Goranitis,3 Chidubem B Ogwulu,2 Helen M Williams,1 Ioannis D Gallos,1 Abey Eapen,4 Jane P Daniels,5 Amna Ahmed,6 Ruth Bender-Atik,7 Kalsang Bhatia,8 Cecilia Bottomley,9 Jane Brewin,10 Meenakshi Choudhary,11 Fiona Crosfill,12 Shilpa Deb,13 W Colin Duncan,14 Andrew Ewer,1 Kim Hinshaw,6 Thomas Holland,15 Feras Izzat,16 Jemma Johns,17 Mary-Ann Lumsden,18 Padma Manda,19 Jane E Norman,14 Natalie Nunes,20 Caroline E Overton,21 Kathiuska Kriedt,9 Siobhan Quenby,22 Sandhya Rao,23 Jackie Ross,17 Anupama Shahid,24 Martyn Underwood,25 Nirmala Vaithilingham,26 Linda Watkins,27 Catherine Wykes,28 Andrew W Horne,14 Davor Jurkovic9 and Lee J Middleton2

1Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
2Institute of Applied Health Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
3Melbourne School of Population and Global Health, University of Melbourne, Melbourne, VIC, Australia
4Carver College of Medicine, University of Iowa Health Care, Iowa City, IA, USA
5Faculty of Medicine and Health Sciences, Queen’s Medical Centre, University of Nottingham, Nottingham, UK
6Sunderland Royal Hospital, City Hospitals Sunderland NHS Foundation Trust, Sunderland, UK
7Miscarriage Association, Wakefield, UK
8 Burnley General Hospital, East Lancashire Hospitals NHS Trust, Burnley, UK
9 University College Hospital, University College London Hospitals NHS Foundation Trust, London, UK
10 Tommy’s, London, UK
11 Royal Victoria Infirmary, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
12 Royal Preston Hospital, Lancashire Teaching Hospitals NHS Trust, Preston, UK
13 Queen’s Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
14 Medical Research Council Centre for Reproductive Health, The Queen’s Medical Research Institute, University of Edinburgh, Edinburgh, UK
15 St Thomas’ Hospital, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
16 University Hospital Coventry, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK
17 King’s College Hospital, King’s College Hospital NHS Foundation Trust, London, UK
18 Reproductive & Maternal Medicine, School of Medicine, Dentistry and Nursing, University of Glasgow, Glasgow, UK
19 The James Cook University Hospital, South Tees Hospitals NHS Foundation Trust, Middlesbrough, UK
20 West Middlesex University Hospital, Chelsea and Westminster Hospital NHS Foundation Trust, Isleworth, UK
21 St Michael’s Hospital, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
22 Biomedical Research Unit in Reproductive Health, Warwick Medical School, University of Warwick, Coventry, UK
23 Whiston Hospital, St Helen’s and Knowsley Teaching Hospitals NHS Trust, Prescot, UK
24 Whips Cross Hospital, Barts Health NHS Trust, London, UK
25 Princess Royal Hospital, Shrewsbury and Telford Hospital NHS Trust, Telford, UK
26 Queen Alexandra Hospital, Portsmouth Hospitals NHS Trust, Portsmouth, UK
27 Liverpool Women’s Hospital, Liverpool Women’s NHS Foundation Trust, Liverpool, UK
28 East Surrey Hospital, Surrey and Sussex Healthcare NHS Trust, Redhill, UK

*Corresponding author a.coomarasamy@bham.ac.uk

Declared competing interests of authors: Jane P Daniels declares membership of the Clinical Trials Unit Standing Advisory Committee. Meenakshi Choudhary declares membership of Health Technology Assessment (HTA) Maternal, Newborn and Child Health (MNCH) Panel and the HTA Prioritisation Committee. Jane E Norman declares membership of the HTA MNCH Panel, that she currently receives funding from the National Institute for Health Research Efficacy and Mechanism Evaluation (EME) programme, that she participates in a Data Monitoring and Ethics Committee for GlaxoSmithKline plc (Brentford, UK) and that she is a paid consultant for Dilafor AB (Solna, Sweden). She was a member of the HTA and EME Editorial Board from 2012 to 2014. Caroline Overton declares that she was a Mylan clinical educator for general practitioner education about hormone replacement therapy and incorporated private practice in April 2017 (now called Bristol Women’s Clinic Ltd).

Published June 2020
DOI: 10.3310/hta24330
Scientific summary

The PRISM RCT
Health Technology Assessment 2020; Vol. 24: No. 33
DOI: 10.3310/hta24330

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

Progesterone, produced by the corpus luteum in the ovaries, helps to prepare the endometrium for implantation of the embryo and thus is an essential hormone for a successful pregnancy. Evidence from several controlled clinical trials suggested that there was a benefit from progesterone therapy, but with insufficient certainty owing to the size of the trials and their methodological weaknesses. This prompted the National Institute for Health and Care Excellence (NICE) (Clinical Guideline 154 on ‘Ectopic Pregnancy and Miscarriage’; National Collaborating Centre for Women’s and Children’s Health. NICE Clinical Guidelines [CG154]. Ectopic Pregnancy and Miscarriage: Diagnosis and Initial Management. London: NICE; 2012) to call for a definitive trial to answer this question.

Objectives

The Progesterone in Spontaneous Miscarriage study was designed to test the hypothesis that, in women with vaginal bleeding in the first 12 weeks of pregnancy, receiving vaginal progesterone (400-mg pessaries, twice daily) as soon as possible after the identification of an intrauterine gestation sac until 16 weeks of gestation increases the rate of live births at ≥34 completed weeks of pregnancy by at least 5% compared with placebo. In addition, an economic evaluation was conducted alongside the trial to assess the relative cost-effectiveness of progesterone compared with placebo.

Design

The Progesterone in Spontaneous Miscarriage trial was a multicentre, double-blind, placebo-controlled randomised trial, with economic evaluation.

Setting

The study was conducted in hospital settings across the UK (48 sites) between 2015 and 2018.

Participants

Participants were women who presented with early pregnancy bleeding that had started in the preceding 4 days, who were in the first 12 weeks of pregnancy and who had an intrauterine gestation sac visible on ultrasonography. Participants were aged 16–39 years at randomisation and gave informed consent.

Interventions

Each participant in the Progesterone in Spontaneous Miscarriage trial received either progesterone or placebo pessaries at a dose of 400 mg twice daily, which were administered vaginally from the day of randomisation to 16 completed weeks of gestation.
Main outcome measures

The primary outcome measure was live birth at ≥ 34 completed weeks of gestation. The secondary outcome measures included ongoing pregnancy at 12 weeks, miscarriage, gestation at delivery, neonatal survival at 28 days of life, congenital anomalies and resource use.

Methods

Participants were randomised online in a 1:1 ratio using a secure internet facility through an integrated trial management system. Minimisation was implemented for age (< 35 or ≥ 35 years), body mass index (< 30 or ≥ 30 kg/m²), fetal heart activity (present or absent), gestation at presentation by date of last menstrual bleed (≤ 42 or > 42 days) and amount of bleeding (pictorial bleeding assessment chart score of ≤ 2 or ≥ 3). Data were collected at three points of outcome assessment after randomisation, up to 28 days after birth. The primary analysis was by intention to treat. A within-trial cost-effectiveness analysis was conducted from the NHS and NHS/Personal Social Services perspective based on the main clinical outcome of this trial.

Results

A total of 4153 women from 48 hospitals in the UK received either progesterone (2079 participants) or placebo (2074 participants). The follow-up rate for the primary outcome was 97.2% (4038 out of 4153 participants). The live birth rate was 75% (1513 out of 2025 participants) in the progesterone group compared with 72% (1459 out of 2013 participants) in the placebo group (relative rate 1.03, 95% confidence interval 1.00 to 1.07; \( p = 0.08 \)). A significant subgroup effect (interaction test \( p = 0.007 \)) was identified for prespecified subgroups by the number of previous miscarriages: none (74% progesterone vs. 75% placebo; relative rate 0.99, 95% confidence interval 0.95 to 1.04; \( p = 0.72 \)); one or two (76% progesterone vs. 72% placebo; relative rate 1.05, 95% confidence interval 1.00 to 1.12; \( p = 0.07 \)); and three or more (72% progesterone vs. 57% placebo; relative rate 1.28, 95% confidence interval 1.08 to 1.51; \( p = 0.004 \)), thus demonstrating a biological gradient by the increasing number of previous miscarriages. A significant post hoc subgroup effect (interaction test \( p = 0.01 \)) was found when we grouped all participants with any number of previous miscarriage(s) (75% in the progesterone group vs. 70% in the placebo group; relative rate 1.09, 95% confidence interval 1.03 to 1.15; \( p = 0.003 \)). There were no significant differences in the occurrence of adverse events.

For secondary outcomes, there was evidence that progesterone may increase the rate of ongoing pregnancy at 12 weeks (83% in the progesterone group vs. 80% in the placebo group; relative rate 1.04, 95% confidence interval 1.01 to 1.07; \( p = 0.01 \)). There was no evidence of a difference in the safety outcomes.

The results of the health economics analysis show that the average cost per participant was £7655 in the progesterone arm and £7572 in the placebo arm, a mean cost difference of £83 (adjusted mean difference £76, 95% confidence interval −£559 to £711) between the two arms. The incremental cost-effectiveness ratio of progesterone compared with placebo was estimated at £3305 per additional live birth at ≥ 34 weeks of gestation. These results suggest that progesterone is likely to be perceived by decision-makers as cost-effective.

Conclusions

Progesterone therapy in the first trimester of pregnancy did not result in a significantly higher rate of live births among women with threatened miscarriage overall. However, an increase in live births was observed in the subgroup of women with early pregnancy bleeding and a history of previous miscarriages. A conclusion on the cost-effectiveness of the PRISM trial would depend on the amount that society is willing to pay to increase the chances of an additional live birth at ≥ 34 weeks.
Trial registration

This trial is registered as Current Controlled Trials ISRCTN14163439, EudraCT 2014-002348-42 and Integrated Research Application System (IRAS) 158326.

Funding

This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full in *Health Technology Assessment;* Vol. 24, No. 33. See the NIHR Journals Library website for further project information.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 3.819

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, the Cochrane Library and Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

Health Technology Assessment (HTA) research is undertaken where some evidence already exists to show that a technology can be effective and this needs to be compared to the current standard intervention to see which works best. Research can evaluate any intervention used in the treatment, prevention or diagnosis of disease, provided the study outcomes lead to findings that have the potential to be of direct benefit to NHS patients. Technologies in this context mean any method used to promote health; prevent and treat disease; and improve rehabilitation or long-term care. They are not confined to new drugs and include any intervention used in the treatment, prevention or diagnosis of disease.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 12/167/26. The contractual start date was in October 2014. The draft report began editorial review in October 2018 and was accepted for publication in May 2019. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2020. This work was produced by Coomarasamy et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).